MYCO — Mydecine Innovations Balance Sheet
0.000.00%
Last trade - 00:00- CA$0.62m
- CA$7.65m
Annual balance sheet for Mydecine Innovations, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 2.19 | 1.5 | 6.96 | 0.038 | 0 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.041 | 0.205 | 0.363 | 0.155 | 0.05 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 2.5 | 5.22 | 8.54 | 0.212 | 0.051 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.515 | 0.565 | 0.01 | 0 | — |
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 9.53 | 7.58 | 9.23 | 0.212 | 0.051 |
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 5.8 | 2.95 | 5.82 | 12.1 | 15 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 5.97 | 7.37 | 10.5 | 12.1 | 15 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 3.56 | 0.211 | -1.28 | -11.9 | -14.9 |
| Total Liabilities & Shareholders' Equity | 9.53 | 7.58 | 9.23 | 0.212 | 0.051 |
| Total Common Shares Outstanding |